Specificity in cancer immunotherapy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
From the earliest days in the field of tumor immunology three questions have been asked: do cancer cells express tumor-specific antigens, does the immune system recognize these antigens, and if so, what is their biochemical nature? We now know that truly tumor-specific antigens exist, that they are caused by somatic mutations, and that these antigens can induce both humoral and cell-mediated immune responses. Because tumor-specific antigens are exclusively expressed by the cancer cell and are often crucial for tumorigenicity, they are ideal targets for anti-cancer immunotherapy. Nevertheless, the antigens that are targeted today by anti-tumor immunotherapy are not tumor-specific antigens, but antigens that are normal molecules also expressed by normal tissues (so-called “tumor-associated” antigens). If tumor-specific antigens exist and are ideal targets for immunotherapy, why are they not being targeted? In this review, we summarize current knowledge of cancer-specific antigens: their identification, immunological relevance and clinical use. We discuss novel tumor-specific epitopes and propose new approaches that could improve the success of cancer immunotherapy, especially for the treatment of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Glycosylation and the Immune System
Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., & Dwek, R. A. (2001) · Science · doi:10.1126/science.291.5512.2370 · Cited by 1,588 · cited 1×
“[74] Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA.”
BackgroundCharacterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105 · cited 1×
“[36] Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al.”
Backgroundβ1-6 Branching of Asn-Linked Oligosaccharides Is Directly Associated with Metastasis
Dennis, J. W., Laferté, S., Waghorne, C., Breitman, M. L., & Kerbel, R. S. (1987) · Science · doi:10.1126/science.2953071 · Cited by 940
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061615598 · Cited by 714
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550 · cited 1×
“[45] Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, et al.”
BackgroundThe testis in immune privilege
Fijak, M., & Meinhardt, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00438.x · Cited by 483
Polysaccharide processing and presentation by the MHCII pathway
Cobb, B. A., Wang, Q., Tzianabos, A. O., & Kasper, D. L. (2004) · Cell · doi:10.1016/j.cell.2004.05.001 · Cited by 340
Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y., Dwek, R. A., McMichael, A. J., & Elliott, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.2.739 · Cited by 184
Haurum, J. S., Høier, I. B., Arsequell, G., Neisig, A., Valencia, G., Zeuthen, J., Neefjes, J., & Elliott, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.1.145 · Cited by 106
Cited by
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720
Self-citationInduction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Microfluidics: A New Tool for Modeling Cancer–Immune Interactions
Boussommier-Calleja, A., Li, R., Chen, M. B., Wong, S. C., & Kamm, R. D. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.12.003 · Cited by 224
“First, because these therapies specifically target certain immune-cancer cell interactions[38], they can have lesser off-target effects.”
Background
Metadata
- Authors
- Schietinger, A., Philip, M., & Schreiber, H.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 20
- Issue
- 5
- Pages
- 276-285
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W1980296501
- Cited by
- 105
- References
- 11
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specificity in cancer immunotherapy. https://app.cochat.ai/papers/10.1016/j.smim.2008.07.001
- The paper
- Schietinger, A., Philip, M., & Schreiber, H. (2008). Specificity in cancer immunotherapy. Seminars in Immunology. https://doi.org/10.1016/j.smim.2008.07.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.